» Articles » PMID: 19366848

Combined Transdermal Testosterone Gel and the Progestin Nestorone Suppresses Serum Gonadotropins in Men

Overview
Specialty Endocrinology
Date 2009 Apr 16
PMID 19366848
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Context: Testosterone (T) plus progestin combinations are the most promising hormonal male contraceptives. Nestorone (NES), a progestin without estrogenic or androgenic activity, when combined with T may be an excellent candidate for male contraception.

Objective: Our objective was to determine the effect of transdermal NES gel alone or with T gel on gonadotropin suppression.

Design And Setting: The randomized, unblinded clinical trial was conducted at two academic medical centers.

Participants: A total of 140 healthy male volunteers participated.

Interventions: One hundred subjects were randomized initially (20 per group) to apply NES gel 2 or 4 mg, T gel 10 g, or T gel 10 g plus NES gel 2 or 4 mg daily for 20 d. Because only about half of the subjects in T plus NES 4 mg group suppressed serum gonadotropins to 0.5 IU/liter or less (suboptimal suppression), two additional groups of 20 men were randomized to apply daily T gel 10 g plus NES gel 6 or 8 mg.

Main Outcome Variable: Suppression of serum LH and FSH concentrations to 0.5 IU/liter or less after treatment was the main outcome variable.

Results: A total of 119 subjects were compliant with gel applications with few study-related adverse events. NES alone reduced gonadotropins significantly but less than T gel alone. Combined T gel 10g plus NES gel 6 or 8 mg suppressed both serum gonadotropins to 0.5 IU/liter or less in significantly more men than either gel alone.

Conclusion: Transdermal NES gel alone had gonadotropin suppression activity. Combined transdermal NES (6 or 8 mg) plus T gel demonstrated safe and effective suppression of gonadotropins, justifying a longer-term study of this combination for suppression of spermatogenesis.

Citing Articles

Management of Male Fertility in Hypogonadal Patients on Testosterone Replacement Therapy.

Fink J, Ide H, Horie S Medicina (Kaunas). 2024; 60(2).

PMID: 38399562 PMC: 10890669. DOI: 10.3390/medicina60020275.


Male contraception: narrative review of ongoing research.

Louwagie E, Quinn G, Pond K, Hansen K Basic Clin Androl. 2023; 33(1):30.

PMID: 37940863 PMC: 10634021. DOI: 10.1186/s12610-023-00204-z.


Emerging concepts in male contraception: a narrative review of novel, hormonal and non-hormonal options.

Service C, Puri D, Hsieh T, Patel D Ther Adv Reprod Health. 2023; 17:26334941221138323.

PMID: 36909934 PMC: 9996746. DOI: 10.1177/26334941221138323.


Post-abortion contraception, an opportunity for male partners and male contraception.

Nguyen B, Jacobsohn T Contraception. 2022; 115:69-74.

PMID: 35870483 PMC: 9561074. DOI: 10.1016/j.contraception.2022.07.004.


Hormonal Male Contraception: Getting to Market.

Page S, Blithe D, Wang C Front Endocrinol (Lausanne). 2022; 13:891589.

PMID: 35721718 PMC: 9203677. DOI: 10.3389/fendo.2022.891589.


References
1.
Liu P, Swerdloff R, Christenson P, Handelsman D, Wang C . Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis. Lancet. 2006; 367(9520):1412-20. DOI: 10.1016/S0140-6736(06)68614-5. View

2.
Kamischke A, Venherm S, Ploger D, von Eckardstein S, Nieschlag E . Intramuscular testosterone undecanoate and norethisterone enanthate in a clinical trial for male contraception. J Clin Endocrinol Metab. 2001; 86(1):303-9. DOI: 10.1210/jcem.86.1.7057. View

3.
. Contraceptive efficacy of testosterone-induced azoospermia in normal men. World Health Organization Task Force on methods for the regulation of male fertility. Lancet. 1990; 336(8721):955-9. View

4.
Handelsman D, Conway A, Howe C, Turner L, Mackey M . Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot. J Clin Endocrinol Metab. 1996; 81(11):4113-21. DOI: 10.1210/jcem.81.11.8923869. View

5.
Li F, Kumar N, Tsong Y, Monder C, Bardin C . Synthesis and progestational activity of 16-methylene-17 alpha-hydroxy-19-norpregn-4-ene-3,20-dione and its derivatives. Steroids. 1997; 62(5):403-8. DOI: 10.1016/s0039-128x(97)00005-6. View